Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 14/20 | 1.00 |
| ▸ | GAB1 | Q13480 | 3/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | AKT2 | P31751 | 1/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 1.00 |
| ▸ | IRS1 | P35568 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283200 | 1.00 | AKT1 (1.00) | AKT1GAB1PDPK1ABCB11AKT2 | |
| SCHEMBL283518 | 1.00 | AKT1 (1.00) | AKT1GAB1PDPK1ABCB11AKT2 | |
| SCHEMBL283309 | 1.00 | AKT1 (1.00) | AKT1GAB1PDPK1ABCB11AKT2 | |
| SCHEMBL283155 | 1.00 | AKT1 (1.00) | AKT1GAB1PDPK1ABCB11AKT2 | |
| SCHEMBL283219 | 1.00 | AKT1 (1.00) | AKT1GAB1PDPK1ABCB11AKT2 | |
| SCHEMBL282536 | 0.95 | AKT1 (1.00) | AKT1GAB1PDPK1ABCB11AKT2 | |
| SCHEMBL11891730 | 0.89 | AKT1 (0.80) | AKT1GAB1PDPK1ABCB11AKT2 | |
| SCHEMBL11891726 | 0.88 | AKT1 (0.78) | AKT1GAB1PDPK1ABCB11AKT2 | |
| SCHEMBL11891720 | 0.88 | AKT1 (0.78) | AKT1GAB1PDPK1ABCB11AKT2 | |
| SCHEMBL11891682 | 0.86 | AKT1 (0.75) | AKT1GAB1PDPK1ABCB11AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 610 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075487-A | Application of PHT-427 in preparing medicine for inhibiting activity of monkey pox core protease | — | 2026-05-26 | — | — | CN | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3664807-B1 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-19 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4615431-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-09-17 | — | — | EP | claimed |
| EP-4604957-A1 | COMBINATIONS OF A SERD FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | claimed |
| US-20250205233-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-06-26 | — | — | US | claimed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | claimed |
| US-20220235330-A1 | METHODS FOR CREATING INTEGRATION-FREE, VIRUS-FREE, EXOGENOUS ONCOGENE-FREE IPS CELLS AND COMPOSITIONS FOR USE IN SUCH METHODS | Cellular Engineering Technologies, Inc. (US) | 2022-07-28 | — | — | US | claimed |
| CN-114746093-A | Method for treating vascular malformations | 德西费拉制药有限责任公司 | 2022-07-12 | — | — | CN | claimed |
| EP-4013417-A1 | METHODS AND COMPOSITIONS FOR TREATING VASCULAR MALFORMATIONS | Deciphera Pharmaceuticals, LLC (US) | 2022-06-22 | — | — | EP | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | claimed |
| US-20190316095-A1 | METHODS FOR CREATING INTEGRATION-FREE, VIRUS-FREE, EXOGENOUS ONCOGENE-FREE IPS CELLS AND COMPOSITIONS FOR USE IN SUCH METHODS | Cellular Engineering Technologies, Inc. (US) | 2019-10-17 | — | — | US | claimed |
| US-20180369264-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-12-27 | — | — | US | claimed |
| EP-3393477-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-10-31 | — | — | EP | claimed |
| WO-2017109778-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-06-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, PI4K2A, PIK3CA | AKT1 18/4885GAB1 4018/4885PDPK1 100/4885 |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | AKT1 3905/4885GAB1 1040/4885PDPK1 4568/4885 |
| US-20250205233-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | AKT1 21/4885GAB1 454/4885PDPK1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.